Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Tetrahydrofuran. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydrofuran SCHEMBL44945 | 1.00 | — | — | |
| Tetrahydrofuran SCHEMBL28650393 | 1.00 | ALDH1A1 (0.53) | ALDH1A1FFAR3LCKFYNSMN1; SMN2 | |
| Acetic Acid SCHEMBL2354574 | 0.97 | ALDH1A1 (0.50) | ALDH1A1FFAR3LCKFYNSMN1; SMN2 | |
| Tetrahydrofuran SCHEMBL7457134 | 0.97 | ALDH1A1 (0.50) | ALDH1A1FFAR3LCKFYNSMN1; SMN2 | |
| Tetrahydrofuran SCHEMBL7645655 | 0.97 | ALDH1A1 (0.50) | ALDH1A1FFAR3LCKFYNSMN1; SMN2 | |
| Tetrahydrofuran SCHEMBL7175965 | 0.97 | ALDH1A1 (0.50) | ALDH1A1FFAR3LCKFYNSMN1; SMN2 | |
| Acetic Acid SCHEMBL4868108 | 0.97 | ALDH1A1 (0.50) | ALDH1A1FFAR3LCKFYNSMN1; SMN2 | |
| Tetrahydrofuran SCHEMBL1056026 | 0.97 | ALDH1A1 (0.50) | ALDH1A1FFAR3LCKFYNSMN1; SMN2 | |
| Tetrahydrofuran SCHEMBL9359499 | 0.97 | ALDH1A1 (0.50) | ALDH1A1FFAR3LCKFYNSMN1; SMN2 | |
| Tetrahydrofuran SCHEMBL7613346 | 0.97 | ALDH1A1 (0.50) | ALDH1A1FFAR3LCKFYNSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720840-B1 | METHODS TO MANUFACTURE 1,3-DIOXOLANE NUCLEOSIDES | UNIV EMORY (US) | 2016-02-03 | — | — | EP | claimed |
| US-20110130559-A1 | Methods to Manufacture 1,3-Dioxolane Nucleosides | GILEAD SCIENCES, INC. (US) | 2011-06-02 | — | — | US | claimed |
| US-7785839-B2 | Methods to manufacture 1,3-dioxolane nucleosides | EMORY UNIVERSITY (US) | 2010-08-31 | — | — | US | claimed |
| EP-1720840-A4 | METHODS TO MANUFACTURE 1,3-DIOXOLANE NUCLEOSIDES | UNIV EMORY (US) | 2009-01-21 | — | — | EP | claimed |
| EP-1720840-A2 | METHODS TO MANUFACTURE 1,3-DIOXOLANE NUCLEOSIDES | EMORY UNIVERSITY (US) | 2006-11-15 | — | — | EP | claimed |
| US-20060036092-A1 | Methods to manufacture 1,3-dioxolane nucleosides | SZNAIDMAN MARCOS | 2006-02-16 | — | — | US | claimed |
| WO-2005074654-A2 | METHODS TO MANUFACTURE 1,3-DIOXOLANE NUCLEOSIDES | EMORY UNIVERSITY (US) | 2005-08-18 | — | — | WO | claimed |
| US-20230365523-A1 | PROCESS FOR PREPARING 3-(CYCLOHEX-1-EN-1-YL)PROPANAL DERIVATIVES | FIRMENICH SA (CH) | 2023-11-16 | — | — | US | disclosed |
| CN-116018334-A | Process for preparing 3- (cyclohex-1-en-1-yl) propanal derivatives | 弗门尼舍有限公司 | 2023-04-25 | — | — | CN | disclosed |
| EP-4153552-A2 | PROCESS AND INTERMEDIATES FOR PREPARING 3-(CYCLOHEX-1-EN-1-YL) PROPANAL DERIVATIVES | Firmenich SA (CH) | 2023-03-29 | — | — | EP | disclosed |
| WO-2022049036-A2 | PROCESS FOR PREPARING 3-(CYCLOHEX-1-EN-1-YL)PROPANAL DERIVATIVES | FIRMENICH SA (CH) | 2022-03-10 | — | — | WO | disclosed |
| EP-1720840-B1 | METHODS TO MANUFACTURE 1,3-DIOXOLANE NUCLEOSIDES | UNIV EMORY (US) | 2016-02-03 | — | — | EP | disclosed |
| US-8420354-B2 | Methods to manufacture 1,3-dioxolane nucleosides | EMORY UNIVERSITY (US) | 2013-04-16 | — | — | US | disclosed |
| EP-0956021-B1 | L-BETA-DIOXOLANE URIDINE ANALOGS FOR TREATING AND PREVENTING INFECTIONS BY EBV, VZV AND HV-8 | UNIV YALE (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20010018440-A1 | L-beta-dioxolane uridine analogs and methods for treating and preventing virus infections | YALE UNIVERSITY AND THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2001-08-30 | — | — | US | disclosed |
| US-6274589-B1 | VIRICIDES TO TREAT EPSTEIN-BARR, VARICELLA-ZOSTER, AND/OR HERPES INFECTIONS; KAPOSI'S SARCOMA | YALE UNIVERSITY | 2001-08-14 | — | — | US | disclosed |
| US-6022876-A | KAPOSI'S SARCOMA; VARICELLA-ZOSTER VIRUS | YALE UNIVERSITY (US) | 2000-02-08 | — | — | US | disclosed |
| EP-0956021-A1 | L-$g(b)-DIOXOLANE URIDINE ANALOGS AND METHODS FOR TREATING AND PREVENTING VIRUS INFECTIONS | YALE UNIVERSITY (US) | 1999-11-17 | — | — | EP | disclosed |
| US-5792773-A | L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection | YALE UNIVERSITY (US) | 1998-08-11 | — | — | US | disclosed |
| WO-1998020879-A1 | L-β-DIOXOLANE URIDINE ANALOGS AND METHODS FOR TREATING AND PREVENTING VIRUS INFECTIONS | YALE UNIVERSITY (US) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060036092-A1 | Methods to manufacture 1,3-dioxolane nucleosides | DCTD, AMPD1, DAD1 | ALDH1A1 163/4885FFAR3 1292/4885LCK 3125/4885 |
| US-20110130559-A1 | Methods to Manufacture 1,3-Dioxolane Nucleosides | DCTD, AMPD1, DAD1 | ALDH1A1 161/4885FFAR3 1239/4885LCK 2949/4885 |
| US-20230365523-A1 | PROCESS FOR PREPARING 3-(CYCLOHEX-1-EN-1-YL)PROPANAL DERIVATIVES | CYP1A1, CYP51A1, HPD | ALDH1A1 125/4885FFAR3 1293/4885LCK 3511/4885 |
| US-20010018440-A1 | L-beta-dioxolane uridine analogs and methods for treating and preventing virus infections | UNG, DDX18, UMPS | ALDH1A1 1027/4885FFAR3 3779/4885LCK 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.